




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :  A61M 5/24	A1	(11) International Publication Number: WO 99/16487  (43) International Publication Date: 8 April 1999 (08.04.99)
(21) International Application Number: PCT/US98/19649		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 21 September 1998 (21.09.98)		
(30) Priority Data: 08/939,776 29 September 1997 (29.09.97) US		
(71) Applicant (for all designated States except US): BECTON DICKINSON AND COMPANY [US/US]; One Becton Drive, Franklin Lakes, NJ 07417-1880 (US).		
(72) Inventors; and		Published
(75) Inventors/Applicants (for US only): BITDINGER, Ralf, V. [DE/US]; 36 West 76th Street, New York, NY 10023 (US). BIRKLAND, Katherine [US/US]; 44 Nimitz Road, Wayne, NJ 07470 (US).		With international search report.
(74) Agent: WARK, Allen, W.; Becton Dickinson and Company, One Becton Drive, Franklin Lakes, NJ 07417-1880 (US).		

(54) Title: DISPOSABLE, PRE-FILLED DRUG CARTRIDGE



## (57) Abstract

This invention relates to a drug cartridge assembly for use with a reusable body assembly of a medication delivery pen. The drug cartridge is disposable and is in the form of a single integral unit having a generally tubular barrel with a distal end defined by an inwardly converging shoulder and an open proximal end. A smaller diameter neck projects distally from the shoulder of the barrel, and is provided with a pierceable and resealable elastomeric seal or septum securely mounted across the open distal end defined by the neck. Medication is pre-filled into the integral cartridge assembly and is retained therein by an elastomeric stopper or plunger. The plunger is in sliding fluid-tight engagement with a tubular wall of the barrel. Distally directed forces on the plunger urge the medication from the cartridge. The proximal end of the tubular barrel is configured for interconnecting the drug cartridge with a pen body assembly and the distal end of the tubular barrel is configured to securely but releasably engage a needle cannula assembly.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**UNITED STATES PATENT APPLICATION**

5

**DISPOSABLE, PRE-FILLED DRUG CARTRIDGE**

10

15

20

**FIELD OF THE INVENTION**

The present invention generally relates to drug delivery devices, and more specifically relates to disposable, pre-fillable drug cartridge for use with a reusable body portion of an injection device for injecting drugs or medicaments into patients which are commonly known in the field as pens.

**BACKGROUND OF THE INVENTION**

Hypodermic syringes are used to deliver selected doses of medication to patients. The prior hypodermic syringe includes a syringe barrel having opposed proximal and distal ends. A cylindrical chamber wall extends between the ends and defines a fluid receiving chamber. The proximal end of the syringe barrel is substantially open and receives a plunger in sliding fluid tight engagement. The distal end of the syringe barrel includes a passage communicating with the chamber. A needle cannula may be mounted to the distal end of the syringe barrel, such that the lumen of the needle cannula communicates with the passage and the chamber of the syringe barrel. Movement of the plunger in a proximal direction draws fluid through the lumen of the needle cannula and into the chamber. Movement of the plunger in a proximal-to-distal direction urges fluid from the chamber and through the lumen of the needle cannula.

Medication to be injected with the prior hypodermic syringe often is stored in a vial having a pierceable elastomeric seal. Medication in the vial is accessed by piercing the elastomeric seal with the needle cannula. A selected dose of the medication may be drawn into the chamber of the syringe barrel by moving the plunger a selected distance in a proximal direction. The needle cannula may be

withdrawn from the vial, and the medication may be injected into a patient by moving the plunger in a distal direction.

Some medication, such as insulin is self-administered. The typical diabetes 5 patient will require injections of insulin several times during the course of a week or day. The required dose of insulin will vary from patient to patient, and for each patient may vary during the course of the day and from day to day. Usually, each diabetes patient will establish a regimen that is appropriate for his or her own medical condition and for his or her lifestyle. The regimen typically includes some 10 combination of a slow or medium acting insulin and a faster acting insulin. Each of these regimens may require the diabetes patient to periodically self-administer insulin in public locations, such as places of employment or restaurants. The required manipulation of the standard hypodermic syringe and vial can be inconvenient and embarrassing in these public environments. Examples of syringes are described in 15 U.S. Patent Nos. 5,250,037 (Bitdinger) and 5,667,495 (Bitdinger), and an example of a filler for mixing insulins is described in U.S. Patent No. 5,542,760 (Chanoch), the disclosures of which are hereby incorporated by reference in their entirety.

Medication delivery pens have been developed to facilitate the self- 20 administration of medication. An example of one such medication delivery pen is described in U.S. Patent No. 5,279,585 (Balkwill), which includes a vial holder into which a vial of insulin or other medication may be received, the disclosure of which is hereby incorporated by reference in its entirety. The vial holder is an elongate generally tubular structure with proximal and distal ends. The distal end of the vial 25 holder includes mounting means for engaging a double-ended needle cannula. The proximal end also includes mounting means for engaging a driver and dose setting apparatus as explained further below. A disposable vial for use with the vial holder

includes a distal end having a pierceable elastomeric seal that can be pierced by one end of a double-ended needle cannula. The proximal end of this vial includes a plunger slidably disposed in fluid tight engagement with the cylindrical wall of the vial. This medication delivery pen is used by inserting the vial of medication into the  
5 vial holder. A pen body then is connected to the proximal end of the vial holder. The pen body includes a dose setting apparatus for designating a dose of medication to be delivered by the pen and a driving apparatus for urging the plunger of the vial distally for a distance corresponding to the selected dose. Other examples of pens are described in U.S. Patent Nos. 5,645,534 (Chanoch), 5,582,598 (Chanoch) and  
10 5,569,214 (Chanoch), the disclosure of which are hereby incorporated by reference in their entirety.

The user of the pen mounts a double-ended needle cannula to the distal end of the vial holder such that the proximal point cannula of the needle cannula pierces the  
15 elastomeric seal on the vial as described, for example, in U.S. Patent No. 5,549,575 (Giambattista et. al.), the disclosure of which is hereby incorporated by reference in its entirety. The user then selects a dose and operates the pen to urge the plunger distally to deliver the selected dose. The user then removes and discards the needle cannula, and keeps the medication delivery pen in a convenient location for the next required  
20 medication administration. The medication in the vial will become exhausted after several such administrations of medication. The user then separates the vial holder from the pen body. The empty vial may then be removed and discarded. A new vial can be inserted into the vial holder, and the vial holder and pen body can be reassembled and used again as explained above.

25

The above described reusable medication delivery pen is effective and much more convenient for self-administration of medication than the typical hypodermic

syringe and separate medication vial. However, it has been found that there is a need for additional features and improvements for such a medication delivery pen. For example, with the increased use of pens for self-injection of drugs other than insulin, there is a need to prevent cross-use of insulin pens with other drugs and/or cross-use 5 of drug cartridges with other pens. The problems associated with cross-use could also pose a potential hazard, where the dose dials of the pens are different, which might result in the administration of the wrong dosage of the drug. This is particularly hazardous where an overdose of insulin could lead to hypoglycemia and ER treatment.

10

Thus, there has been a need for a pen, as well as a drug cartridge assembly, which would eliminate the problems and limitations associated with the prior devices discussed above, most significant of the problems being cross-use of the pen with other drug cartridge assemblies and/or cross-use of the drug cartridge assembly with 15 other pens.

#### SUMMARY OF THE INVENTION

In contrast to the prior devices discussed above, it has been found that a pen 20 particularly suited for use in reducing or otherwise eliminating cross-use can be constructed in accordance with the present invention. Specifically, the pen and the drug cartridge assembly of the present invention are keyed, i.e., they have a connection interface which mechanically prevents the cross-use of cartridge assemblies among designated pens by, for example, using matching threads, bayonets 25 or snap fits on the pen and the holding sleeve of the drug cartridge assembly. Also, the cartridge assembly can have an embedded drug cartridge, not readily separable from each other.

Another object of the present invention is to improve the design of the drug cartridge and holder sleeve so that they are a single integral unit for containing the drug, with a rubber septum for multiple needle penetrations along with a standard thread to attach the pen needle. On the far end of the pen needle thread, a connection interface prevents connection to pens other than the one for which use of the drug container is designed. In this way, the drug cartridge assembly will have minimal dead space and an insert molded rubber septum.

10      **BRIEF DESCRIPTION OF THE DRAWINGS**

The various features, objects, benefits, and advantages of the present invention will become more apparent upon reading the following detailed description of the preferred embodiment(s) along with the appended claims in conjunction with the 15 drawings, wherein like reference numerals identify corresponding components, and:

Fig. 1 is a top view of the injection pen of the present invention, with Fig. 1A being a end view;

20      Fig. 2 is a cross-sectional view of the injection pen shown in Fig. 1 with the lead screw retracted;

Fig. 3 is a partial, cross-sectional view of the injection pen similar to Fig. 2 with the lead screw retracted and a drug vial retained therein;

Fig. 4 is an exploded, side view of the cartridge assembly of the present invention and the drug cartridge and the corresponding portion of the pen shown in Fig. 3;

5 Fig. 5 is a partial, cross-sectional view of the cartridge assembly shown in Fig. 4 assembled;

Fig. 6 is a partial, cross-sectional view of an alternative embodiment of the cartridge assembly of the present invention;

10

Fig. 7 is a partial, cross-sectional view of another alternative embodiment of the cartridge assembly of the present invention;

15

Fig. 8 is a partial, cross-sectional view of yet another alternative embodiment of the cartridge assembly of the present invention; and

Fig. 9 is a partial, cross-sectional view of yet another alternative embodiment of the cartridge assembly of the present invention.

20

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT(S)

The medication delivery pen of the present invention is illustrated in Figs. 1 through 5, with the pen being generally designated 10. As shown in Figs. 1-3, the pen includes a pen body assembly 12, a cartridge assembly 14 and a cap 16, with the cartridge assembly being situated between the body assembly and the cap 16 and typically having sufficient medication for several doses. The pen body assembly and the cartridge assembly are keyed, i.e., they have a connection interface which

mechanically prevents the cross-use of cartridges among designated pens by, for example, threadedly engaged by corresponding threads and grooves, bayonet threads and grooves, snap fits or a pair of lugs that mate in a reverse Luer-lock manner. In addition, all of these elements have a generally cylindrical configuration and are  
5 arranged coaxially from opposed proximal and distal ends 18 and 20 of the pen 10 respectively to define a generally cylindrical housing which can easily be handled by a patient or medical attendant.

Referring to Figs. 1 and 2, and in greater detail in Fig. 3, the body assembly 12  
10 is used to set a desired dose of medication to be delivered by the pen 10 and includes an advancing member preferably in the form of a lead screw 22 with a distal end 24 movable in the distal direction based on the dose set by a dose setting mechanism within the pen body 12. The dose setting mechanism determines the distance through which lead screw 22 is to be moved during the injection of medication by the pen 10.  
15 It is understood, however, that variations from this preferred embodiment may be provided, and are considered to be within the scope of the subject invention. Particularly, the specific construction of the pen body 12, including the mechanisms for advancing the lead screw, may include those, for example, disclosed in U.S. Patent Nos. 5,279,585 (Balkwill), 5,279,586 (Balkwill), 5,549,575 (Giambattista et. al.),  
20 5,569,214 (Chanoch), 5,582,598 (Chanoch) and 5,645,534 (Chanoch), and co-pending U.S. Patent Application Serial No. 08/314,179 (Chanoch et. al.), the disclosures of which are hereby incorporated by reference in their entirety. Accordingly, the particular pen body is not essential to the present invention and is merely a matter of choice.

25

As shown in Figs. 1-3, and in greater detail in Figures 4 and 5, the cartridge assembly 14 is divided into two parts, i.e., an upper vial retainer 30 and a lower vial

retainer 32, with the lower vial retainer defining a vial retaining cavity 34 formed in the lower vial retainer. As explained further herein, one end 36A of the upper vial retainer 30 is preferably dimensioned and configured to threadedly engage one end 38A of the lower vial retainer 32 and the other end 36B of the lower vial retainer is 5 configured to securely but releasably engage a needle cannula assembly (not shown). The particular needle cannula assembly is not essential to the present invention and may include the type disclosed in co-pending U.S. Patent Application (P-4059) filed on September 12, 1997 and entitled "PEN NEEDLE ASSEMBLY," the disclosure of which is hereby incorporated by reference in its entirety. The upper and lower 10 retainers 30, 32 both are described in greater detail below.

The cartridge assembly 14, as shown in Figs. 3, 4 and 5, includes a drug vial or cartridge 40, with the cavity 34 dimensioned and configured to securely receive and retain the drug cartridge therein. The drug cartridge 40 includes a generally tubular 15 barrel 42 with a distal end 44A defined by an inwardly converging shoulder 46 and an open proximal end 44B. A smaller diameter neck 48 projects distally from the shoulder 46 of the barrel 42, and is provided with a large diameter annular bead (not shown) extending circumferentially thereabout at the extreme distal end of the neck. A pierceable and resealable elastomeric seal or septum 50 is securely mounted across 20 the open distal end defined by the neck 48. The seal 50 is held in place by a metallic sleeve 52 which is crimped around the circumferential bead at the distal end of the neck 48. Medication is pre-filled into the drug cartridge 40 and is retained therein by an elastomeric stopper or plunger 54. The plunger 54 is in sliding fluid-tight engagement with the tubular wall of the barrel 42. Distally directed forces on the 25 plunger 54 urge the medication from the pen as explained further below.

The portion of the lower retainer 32 defining the cavity 34 is of substantially uniform diameter which is slightly greater than the diameter of the vial barrel 42. The interior of the upper vial retainer 30 includes an inwardly extending annular portion or stop 60 dimensioned to prevent the drug cartridge 40 from moving within the vial retainers 30, 32. In this way, when the drug cartridge 40 is inserted into the cavity 34 and the vial retainers 30, 32 threadedly engaged, the drug cartridge 40 is securely held in the cavity 34 at the open proximal end 44B of the tubular barrel 42 by the annular stop 60. More particularly, the neck 48 and crimped metallic sleeve 52 of the drug cartridge 40 are inserted in a proximal to distal direction into the open proximal end of the lower retainer 32 with the crimped metallic sleeve 52 eventually passing entirely into the lower retainer 32, which will require entry of the crimped metallic sleeve into the portion thereof for mounting the needle cannula assembly. Then, with the vial retainers 30, 32 threadedly engaged, the open proximal end 44 of the drug vial 40 abuts the stops 60 of the upper vial retainer 30.

15

Preferably, when using standard drug vials or cartridges 40, the vial retainers 30, 32 are permanently secured to one another by glue, locking threads or other fastening means. In this way, the cartridge assembly 14 with the drug vial 40 secured therein may be disposed of after being used.

20

The pen body assembly 12 includes an array of threads 62 for threaded engagement with the threaded other end 36B of the upper vial retainer 30, and when threadedly engaged, the plunger 54 is disposed in sliding fluid tight engagement in the cartridge assembly 40. As shown in Fig. 3, the lead screw 22 initially is disposed substantially adjacent the plunger 54 of the drug cartridge 40. The portion of drug cartridge 40 between the plunger 54 and the seal 50 is filled with a medication 66. In this way, advancement of the plunger 54 causes the medication 66 to be forced from the drug cartridge 40 through the needle cannula.

Preferably, the pen body assembly 12 is reusable and the drug cartridge 40 in the cartridge assembly 14 will contain a volume of medication 66 sufficient for administration of several doses. After exhaustion of the medication 66, the cartridge assembly 14 will be threadedly disengaged from pen body assembly 12 and the drug cartridge 40 discarded. A new assembly containing a drug cartridge may then be mounted to the reusable pen body assembly 12.

The assembled reusable pen body assembly 12 and cartridge assembly 14 may be stored until a selected dose of medication is required. Just prior to use, a needle cannula assembly may be threadedly engaged to distal end 38B of cartridge assembly 14. This threaded engagement will cause a proximal tip of a needle cannula to the pierce the seal 50 and provide communication with medication 66.

A desired dose of medication may be set by rotating a dose knob 70 located at the distal end 20 of the pen which will cause advancement of the lead screw 22 into the cavity 34 of the cartridge assembly 14. When the desired dose is set, injection is achieved by merely pushing on actuator button 72 and the lead screw 22 will be advanced axially into cartridge assembly 14. This axial advancement of lead screw 22 causes distal end 24 thereof to come in contact with the plunger 54 and urge the plunger distally into the drug cartridge 40, and hence causes the medication 66 to be injected through the needle cannula. Injection will be terminated when the dose knob 70 is fully depressed into engagement with the pen body assembly 12.

Upon completion of the injection, the needle cannula assembly may be disengaged from the cartridge assembly 14 and safely discarded. The cap 16 may be mounted over cartridge assembly 14, and the pen 10 may be stored or carried in a

convenient location until the next dose of medication is required. A subsequent dose of medication will be set in exactly the manner as described above. However, for such a subsequent dose, the plunger 54 will be in a partly advanced position as a starting point. Dose setting and injections can be carried out until all of medication 66  
5 has been used. The cartridge assembly 14 may then be threadedly disengaged from pen body assembly 12, and slidably separated from the lead screw 22 and discarded in order to be replaced as described above.

Fig. 6 shows an alternative embodiment of the cartridge assembly 114 which  
10 is disposable and includes an upper vial retainer 130 and a lower vial retainer 132. In this embodiment, once a drug cartridge 140 is placed in the cavity 134, the vial retainers 130, 132 are permanently secured to one another by glue or other fastening means 190. In this way, upon utilization of the medication, the drug cartridge assembly 114 along with the empty drug cartridge 140 may be disengaged from the  
15 pen body assembly and safely discarded.

Fig. 7 shows another alternative embodiment of the cartridge assembly 214 which is disposable and is in the form of a single integral unit having a generally tubular barrel 242 with a distal end 244A defined by an inwardly converging shoulder  
20 246 and an open proximal end 244B. A smaller diameter neck 248 projects distally from the shoulder 246 of the barrel 242, and is provided with a pierceable and resealable elastomeric seal or septum 250 securely mounted across the open distal end defined by the neck 248. Medication is pre-filled into the integral cartridge assembly 214 and is retained therein by an elastomeric stopper or plunger 254. The plunger 254  
25 is in sliding fluid-tight engagement with the tubular wall of the barrel 242. Distally directed forces on the plunger 254 urge the medication from the pen as explained interconnection with the preferred embodiment. In this embodiment, the proximal

end 244B of the integral cartridge assembly 214 include bayonet threads 280 which are engageable with corresponding grove 282 formed in the distal end of the pen body 212. The distal end 244A of the tubular barrel is configured to securely but releasably engage a needle cannula assembly (not shown).

5

The cartridge assembly 214 shown in Fig. 7 may be assembled and pre-filled by any suitable means, including those disclosed, for example, in U.S. Patent Nos. 5,279,585 (Balkwill), 5,531,255 (Vacca), 5,519,984 (Veussink et al.), 5,373,684 (Vacca), 5,207,983 (Liebert et al.), 4,718,463 (Jurgens, Jr. et al.), and 4,628,969 (Jurgens, Jr. et al.), and PCT Application No. WO 94/13328 (Hagen), the disclosures of which are hereby incorporated by reference in their entirety.

Fig. 8 shows yet another alternative embodiment of the cartridge assembly 314 which is disposable and includes single vial retainer 332. However, a stop has been situated in the distal end 338B of the vial retainer 332 which permit the drug cartridge 340 to be inserted into the cavity 334 in one direction but resists removal of the drug cartridge, i.e., the insertion force is less than the removal force. Specifically, protrusions 360 project inwardly and extend along the neck 348 of the drug cartridge 40 to securely retain it in the cartridge assembly. In this way, upon utilization of the medication, the drug cartridge assembly 314 along with the empty drug cartridge 340 may be disengaged from the pen body assembly and safely discarded.

Fig. 9 shows yet another alternative embodiment of the cartridge assembly 414 which is disposable and includes single vial retainer in which a flexible vial or drug container 440 such as a pouch can be inserted into the cartridge assembly. Attached by treads or the like to the end 438B of the cartridge assembly is a cannula 490 having a double ended needle 492. In this way, upon movement of the plunger or stopper

454, the proximal end of the needle 492 pierces the drug container to permit the drug to be released therefrom as the container collapses.

The particular material of which the cartridge assembly is made is not essential  
5 to the present invention but preferably includes a polymeric material such as polycarbonate. However, the particular material is a matter of choice depending upon availability, the manufacturing process used and the intended use of the cartridge assembly. For example, where the cartridge assembly 214 is pre-filled with the medication, the polymeric material must be compatible with the medication contained  
10 therein.

It should be appreciated from the detailed description of the preferred embodiments, that the particular means by which the pen body assembly 12 and the cartridge assembly are keyed, i.e., engaged so as to reduce or otherwise eliminate cross-use is essential and may be threadedly engaged by corresponding threads and grooves, bayonet threads and grooves, snap fits or a pair of lugs that mate in a reverse Luer-lock manner. In this way, the pen body assembly 12 includes either a female or male mating member and the cartridge assembly 14 includes a corresponding female or male mating member engageable with one another for interconnecting the two assemblies, with the mating members selected so as to prevent cross-use with other assemblies, e.g., the pitch of the threads may be angled so as to mate only with one another and not with other assemblies.  
15  
20

Also, the cartridge holder sleeve can have an embedded cartridge, not readily  
25 separable from each other as described in connection with one alternative embodiment. In addition, the drug cartridge can be designed as a single integral unit

for containing the drug as described in connection with another alternative embodiment.

While the preferred embodiments of the present invention have been described  
5 so as to enable one skilled in the art to practice the device of the present invention, it  
is to be understood that variations and modifications may be employed without  
departing from the concept and intent of the present invention as defined in the  
following claims. The preceding description is intended to be exemplary and should  
not be used to limit the scope of the invention. The scope of the invention should be  
10 determined only by reference to the following claims.

What is claimed is:

1. A disposable, pre-fillable drug cartridge for use with a reusable body assembly of a medication delivery pen, said drug cartridge comprising:
  - 5 a generally tubular barrel having a distal end and an open proximal end, with a chamber defined by a tubular wall of the barrel extending between said distal end and said proximal end;
  - sealing means associated with the distal end of said tubular barrel for sealing the distal end of said tubular barrel;
  - 10 plunger means associated with the open proximal end of said tubular barrel in sliding fluid-tight engagement with the tubular wall of the barrel for selective engagement with an advancing member so that distally directed forces on the plunger urge a medication pre-filled in the chamber from the cartridge; and
  - 15 mating means for releasably interconnecting said drug cartridge with a pen body assembly and said mating means being associated with the proximal end of said tubular barrel.
2. The drug cartridge of Claim 1, wherein said mating means includes an array of threads on said proximal end of said tubular barrel.
  - 20
  3. The drug cartridge of Claim 2 wherein said array of threads on the proximal end of said tubular barrel define internal threads in said tubular barrel.
  4. The drug cartridge of Claim 1 wherein said distal end of the tubular barrel is configured to securely but releasably engage a needle cannula assembly.
    - 25

5. The drug cartridge of Claim 1 wherein said generally tubular barrel is made of a polymeric material.

6. The drug cartridge of Claim 1 further comprising a medication  
5 contained in said chamber.

7. A disposable, pre-fillable drug cartridge for use with a reusable body assembly of a medication delivery pen, said drug cartridge comprising:

10 a generally tubular barrel made of a polymeric material having a distal end and an open proximal end, with a chamber defined by a tubular wall of the barrel extending between said distal end and said proximal end;

sealing means associated with the distal end of said tubular barrel for sealing the distal end of said tubular barrel;

15 an elastomeric plunger associated with the open proximal end of said barrel in sliding fluid-tight engagement with the tubular wall of the barrel;

medication contained in the chamber and retained therein by the seal and plunger so that distally directed forces on the plunger urge the medication from the cartridge; and

20 mating means for releasably interconnecting said drug cartridge with a pen body assembly and said mating means being associated with the proximal end of said tubular barrel.

8. The drug cartridge of Claim 7, wherein said mating means includes an array of threads on said proximal end of said tubular barrel.


25

9. The drug cartridge of Claim 8 wherein said array of threads on the proximal end of said tubular barrel define internal threads in said tubular barrel.

10. The drug cartridge of Claim 7 wherein said distal end of the tubular barrel is configured to securely but releasably engage a needle cannula assembly.


5        11. The drug cartridge of Claim 7 wherein said medication is contained within a flexible container and a needle cannula attached to distal end of the tubular barrel with said cannula included a double ended needle so that one end of said double ended needle can pierce said flexible container.

1/8



2/8


FIG-2



SUBSTITUTE SHEET (RULE 26)

3/8

FIG-3



SUBSTITUTE SHEET (RULE 26)

4/8

FIG-4






FIG-5



5/8



6/8





FIG-7


7/8

FIG-8



8/8

FIG-9



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 98/19649

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61M5/24

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 91 17 140 U (HOECHST AG) 20 June 1996 see page 2, line 19 - line 23 see page 2, line 28 - line 30 see figures 1,4	1,6
Y	---	2-5,7
Y	WO 90 00073 A (BRUNEL) 11 January 1990 see page 4, line 5 - line 6 see page 7, line 11 - line 1 see claim 1; figures 3,6,9	5,7
A	---	1
Y	US 2 685 878 A (SEIFERT ET AL.) 10 August 1954 see column 2, line 11 - line 16 see figures 1,2	2-4
A	---	8-10
	-/-	

Further documents are listed in the continuation of box C

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

12 January 1999

19/01/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patenttaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Sedy, R

**INTERNATIONAL SEARCH REPORT**

International Application No PCT/US 98/19649	
---	--

**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	FR 1 320 820 A (STEINER) 4 June 1963 see page 2, right-hand column, line 53 - page 3, left-hand column, line 13 see figure 5 ---- EP 0 701 832 A (BECTON DICKINSON AND COMPANY) 20 March 1996 see column 6, line 21 - line 25 see column 8, line 32 - line 48 see figure 1 see claims 1,10; figure 1 & US 5 558 259 A cited in the application -----	11
A		1,4-7,10

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/19649

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
DE 9117140	U	20-06-1996	DE 4025717 A CA 2049092 A EP 0471335 A IE 68055 B IT 229112 Y JP 4244166 A PT 98656 A US 5728076 A		20-02-1992 15-02-1992 19-02-1992 15-05-1996 24-06-1998 01-09-1992 30-09-1993 17-03-1998
WO 9000073	A	11-01-1990	FR 2633520 A EP 0393166 A		05-01-1990 24-10-1990
US 2685878	A	10-08-1954	NONE		
FR 1320820	A	04-06-1963	NONE		
EP 701832	A	20-03-1996	US 5549575 A CA 2156696 A JP 8098886 A		27-08-1996 14-03-1996 16-04-1996

**THIS PAGE BLANK (USPTO)**